Contact Us
Careers
Press Releases
LinkedIn
About Us
Executive Leadership Team
Board of Directors
Scientific Advisory Board
Medicines
Pipeline
Anaphylm
Libervant
Technologies
Services
Investors
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
Quarterly Results
Contact Us
Careers
Press Releases
Linkedin
Meaningful
improvements.
Innovative
delivery.
We're advancing medicines to bring meaningful improvements to patients' lives through innovative science and delivery technologies.
Learn about our pipeline
2.5+ billion doses
and counting
Our PharmFilm® technology is behind trusted, high-quality brands that have simplified treatment regimens and improved patients’ lives
Learn about our medicines
Two breakthrough
technologies.
Endless possibilities.
Our core technologies feature PharmFilm, with a proven track record of transformational drug delivery, and AdrenaVerse—our next frontier of innovation.
Learn about our technologies
Manufacturing
products sold
worldwide
Backed by 20+ years of experience, we manufacture and package trusted products for global brands, all made in the USA.
Learn about services
01.
Pipeline
02.
Medicines
03.
Technologies
04.
Services
Our success is proven
1
FDA approvals
with more in the pipeline
1
+ patents
filed in the U.S. and worldwide
1
expected launches
in the U.S. by 2027
0
+ billion
PharmFilm® doses shipped worldwide
$
0
billion
in potential peak annual net sales from pipeline assets
Learn more about us
Latest News
View all press releases
February 25, 2026
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
Read More
February 24, 2026
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
Read More
February 23, 2026
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Read More
February 20, 2026
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
Read More
February 18, 2026
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
Read More
February 02, 2026
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Read More
INVESTOR RELATIONS
Invest in the future of
simplified medicine delivery
Our patient-centric approach guides the way
NASDAQ: AQST
4.00
USD
-0.11
(
-2.68
%) Today
Events and presentations
Latest ESG Sustainability Report
Press releases
SEC Filings